Emergent BioSolutions secures $62.4M contract modification for BAT

The company states: “Emergent BioSolutions (EBS) announced it has been awarded a $62.4M contract modification from the Administration for Strategic Preparedness and Response, a division of the United States Department of Health and Human Services for BAT(R) (Botulism Antitoxin Heptavalent. The modification has been made to the existing 10-year contract with ASPR whereby Emergent will supply BAT(R), an antitoxin used in the treatment of symptomatic botulism following suspected or confirmed exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in both adults and pediatric patients. This update is a critical step toward preserving access to medical countermeasures to address potential biological threats from botulism. The types and quantities of products that should be maintained in a stockpile will depend on the population requiring protection, the products available for meeting the threat, as well as government resources and priorities.”